SecBot SecBot
8-K ·Filed May 5, 2026

OCGN

Ocugen, Inc.
MIXED
Impact 6/10
Horizonweeks Processed6mo ago SEC0001104659-26-055411
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

Monitor stock price action around the $2.68 conversion price, which could act as a ceiling in the near term. The offering removes near-term bankruptcy risk but adds overhang from potential dilution. Watch for further clinical data readouts (OCU400 Phase 3 topline in Q1 2027) as catalysts.

DirectionMixed
Confidencehigh
Horizonweeks

Price Chart

Loading chart...

Executive Summary

Ocugen reported Q1 2026 GAAP EPS of -$0.06, missing consensus of -$0.05, while collaborative arrangement revenue of $1.5M beat the $358K estimate. The company simultaneously priced $115M (upsized to $130M) of 6.75% convertible senior notes due 2034, with net proceeds of ~$99.5M used to repay $32.7M of high-cost Avenue debt and extend cash runway into 2028. The combination of an EPS miss and material convertible dilution tempers the positive clinical milestones.

Key Financial Metrics

EPS
−$0.06
est −$0.05 · -16.7%
Revenue
$1.5M
est $358.0K · +328.2% · +3.5% YoY
Rating
miss

Key Facts

  • Q1 2026 GAAP EPS -$0.06 vs consensus -$0.05 (16.7% miss)
  • Q1 2026 revenue $1.533M (mostly collaborative) vs consensus $358K (beat)
  • Net loss widened to $19.2M from $15.4M YoY; operating expenses up 21%
  • Priced $115M (option for +$15M) of 6.75% convertible senior notes due 2034
  • Conversion price $2.68 (45% premium to $1.85 recent close); convertibility starts May 2027
  • ~$32.7M of proceeds to repay Avenue debt (12.5% interest); cash runway extended into 2028
  • Cash and equivalents pro forma ~$112M at closing (or $127M if all warrants exercised)
  • Positive clinical updates: Phase 3 RP enrollment complete, Phase 2/3 Stargardt enrollment complete, Phase 2 GA data showing 31% lesion reduction

Financial Impact

EPS miss of $0.01 vs consensus; convertible notes represent ~18% of market cap dilution potential at conversion

epsdilutioncashRunwayinterestExpense

Risk Factors

  • Dilution from note conversion (up to ~42.9M shares if fully converted at initial rate)
  • EPS miss indicates worsening cost trajectory; operating expenses rising faster than revenue
  • Clinical trial risk: Phase 3 data for RP and Stargardt not yet available
  • Revenue concentration in small collaborative arrangements

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
92% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 8 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-055411
Document: tm2613584d1_8k.htm0001104659-26-055411
Document: tm2613584d1_ex99-2.htm0001104659-26-055411
Document: tm2613584d1_ex99-3.htm0001104659-26-055411
Document: 0001104659-26-055411-index-headers.html0001104659-26-055411
Document: 0001104659-26-055411-index.html0001104659-26-055411
Document: 0001104659-26-055411.txt0001104659-26-055411
8-K Data (Synthetic)0001104659-26-055411

Track record

23 reports on OCGN

Performance horizon

3 of 6 bullish or bearish reports moved the stock their way by T+1. Best: +20.49% at T+20 after the Jun 11, 2026 report. 4 of 6 went positive at some point.

Filters
  1. Nov 10, 20266d ago 8-K Neutral 4/10 Entry $0.9500 to $0.9604 Now $0.7730 −18.63% ▲ +1.09% −0.22% vs SPY
  2. Nov 10, 20266d ago Press Release Neutral 4/10 Entry $0.9500 to $0.9604 Now $0.7730 −18.63% ▲ +1.09% −0.22% vs SPY
  3. Nov 6, 202610d ago DEFA14A Neutral 2/10 Entry $0.9721 to $0.9500 Now $0.7730 −20.48% ▼ −2.27% −1.91% vs SPY
  4. Nov 6, 202610d ago DEFA14A Neutral 3/10 Entry $0.9721 to $0.9500 Now $0.7730 −20.48% ▼ −2.27% −1.91% vs SPY
  5. Nov 4, 202612d ago 8-K Neutral 4/10 No price data
  6. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $0.8745 to $0.8165 Now $0.7730 −11.61% ▼ −6.63% −2.22% vs SPY
  7. Oct 15, 20264w ago 8-K Neutral 5/10 Entry $0.8137 to $0.7803 Now $0.7730 −5.00% ▼ −4.10% −3.00% vs SPY
  8. Oct 14, 20264w ago 8-K Mixed 5/10 Entry $0.8137 to $0.7803 Now $0.7730 −5.00% ▼ −4.10% −3.00% vs SPY
  9. Oct 9, 20265w ago 144 Neutral 2/10 Entry $0.9472 to $0.8854 Now $0.7730 −18.39% ▼ −6.52% −6.51% vs SPY
  10. Sep 1, 202610w ago Press Release Bullish 7/10 Entry $1.33 to $1.32 Now $0.7730 −41.88% ▼ −0.75% −1.20% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens in 6h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 5, 2026